Nasdaq
$3.52▲ 1.73%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $290.6MShares out 82.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
23- 1d agoAfter-hours26.10.24 05:57144Ownership#●●●#●●●
Opus Genetics, Inc.Bullish
Insider Yerxa Benjamin R of Opus Genetics, Inc. has filed a Form 144 to report the proposed sale of company securities. This filing indicates a divestment of shares by an insider, and investors should consider the potential impact of this insider selling on the stock price.…more
$3.52+1.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 1d agoAfter-hours26.10.24 05:04144Ownership
Opus Genetics, Inc.
Insider Gagnon Robert E. has filed a Form 144 regarding the proposed sale of shares in Opus Genetics, Inc. This filing formally discloses the insider's intent to sell company stock in the open market.…more
$3.52+1.73%vs prev closeView filingShare - 1d agoRegular26.10.24 03:48144Ownership
Opus Genetics, Inc.
George Magrath, an insider at Opus Genetics, Inc., has filed a Form 144 to report the proposed sale of company shares. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more
$3.52+1.73%vs prev closeView filingShare
22 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:03#●●●#●●●#●●●
Opus Genetics Receives FDA Clearance for OPGx-RDH12 IND
Opus Genetics has received FDA clearance for its Investigational New Drug (IND) application for OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis. This milestone allows the company to advance the treatment into clinical development for this rare inherited retinal disease.…more
$3.52+1.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.16Regular26.10.17 01:00
●●●●●●●● ●●●●● ●●●●●●
Opus Genetics announced FDA approval for its phentolamine ophthalmic solution 0.75% to treat presbyopia, triggering a milestone payment for the company. The product will be commercialized in the U.S. by its partner, Viatris, expanding the drug's existing indications.…more
$3.52+1.73%vs prev close - 10.15After-hours26.10.16 05:00
●●●●●●●● ●●●●● ●●●●●●
Opus Genetics presented positive interim clinical data showing visual function improvements for its OPGx-BEST1 and OPGx-LCA5 gene therapy candidates. Investors should remain cautious as these are early-stage clinical results pending further development and final validation.…more
$3.52+1.73%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report